The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate
Abstract
PURPOSE: To compare two doses of letrozole (0.5 mg and 2.5 mg every day) and megestrol acetate (40 mg qid) as endocrine therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens. PATIENTS AND METHODS: This double-blind, randomized, multicenter, multinational study enrolled 602 patients, all of whom were included in the primary analysis in the protocol. Patients had advanced or metastatic breast cancer with evidence of disease progression while receiving continuous adjuvant antiestrogen therapy, had experienced relapse within 12 months of stopping adjuvant antiestrogen therapy given for at least 6 months, or had experienced disease progression while receiving antiestrogen therapy for advanced disease. Tumors were required to be estrogen receptor– and/or progesterone receptor–positive or of unknown status. Confirmed objective response rate was the primary efficacy variable. Karnofsky Performance Status and European Organization for Research and Treatment of Cancer quality-of-life assessments were collected for 1 year. RESULTS: There were no statistically significant differences among the three treatment groups for overall objective tumor response. Patients treated with letrozole 0.5 mg had improvements in disease progression (P = .044) and a decreased risk of treatment failure (P = .018), compared with patients treated with megestrol acetate. Letrozole 0.5 mg showed a trend (P = .053) for survival benefit when compared with megestrol acetate. Megestrol acetate was more likely to produce weight gain, dyspnea, and vaginal bleeding, and the letrozole groups were more likely to experience headache, hair thinning, and diarrhea. CONCLUSION: Given a favorable tolerability profile, once-daily dosing, and evidence of clinically relevant benefit, letrozole is equivalent to megestrol acetate and should be considered for use as an alternative treatment of advanced breast cancer in postmenopausal women after treatment failure with antiestrogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., Franzini, L., Williams, A., de Haes, H. C., Hopwood, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2756 · Cited by 1,220
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Self-citationEndocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399
Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichardt, P., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008226721932 · Cited by 259
Jonat, W., Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00014-3 · Cited by 254
Bhatnagar, A. S., Häusler, A., Schieweck, K., Lang, M., & Bowman, R. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90460-3 · Cited by 246
Buzdar, A. U., Jones, S. E., Vogel, C. L., Wolter, J., Plourde, P., Webster, A., & for the Arimidex Study Group (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<730::aid-cncr10>3.0.co;2-0 · Cited by 207
Self-citation(1993) · PubMed · Cited by 130
Hamilton, A. L., & Piccart, M. J. (1999) · Annals of Oncology · doi:10.1023/a:1008368300827 · Cited by 118
Demers, L. M., Lipton, A., Harvey, H. A., Kambic, K. B., Grossberg, H., Brady, C., & Santen, R. J. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90283-3 · Cited by 83
Self-citation
Cited by
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Aromatase Inhibitors in the Treatment of Breast Cancer
Brueggemeier, R. W., Hackett, J. C., & Diaz-Cruz, E. S. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0015 · Cited by 484
Metadata
- Authors
- Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-07-15
- Volume
- 19
- Issue
- 14
- Pages
- 3357-3366
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1839333839
- Cited by
- 365
- References
- 14
- FWCI
- 31.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate. https://app.cochat.ai/papers/10.1200/jco.2001.19.14.3357
- The paper
- Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C. (2001). Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2001.19.14.3357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.